# Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

Study · id `cardio:ct-nct01131299` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01131299](<https://clinicaltrials.gov/study/NCT01131299>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01131299

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT01131299. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-21.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT01131299, source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01131299, source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01131299, source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01131299, source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)
- Results first posted: 2016-10-21 (ClinicalTrials.gov record NCT01131299, source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01131299, source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01131299-2016-10-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
- Condition: Cardiovascular Disease
- Intervention (Other): Placebo
- Intervention (Drug): Alpha cyclodextrin
- Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- Lead sponsor class: NIH

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids (`cardio:pubmed-27405337`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e72b73e21f4b951f7704a6f0a32a24e72afdd06a0887a4a8ab26b6fcea8e3099
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
